piromelatine
Small moleculeexperimental
Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01114126)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2[nH]cc(CCNC(=O)c3cc(=O)cco3)c2c1- Mol. weight
- 312.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPiromelatine ↗
- ChEMBLCHEMBL4297523 ↗
Also known as
- n-(2-(5-methoxy-indol-3-yl)-ethyl)-4-oxo-4h-pyran-2-carboxamide
- neu-p11
- neu-p11
- neu-p11
- piromelatine
- piromelatine
- piromelatine
- piromelatine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05267535 | Phase 2/Phase 3 (Phase 3) | May 31, 2022 | Neurim Pharmaceuticals Ltd., Syneos Health, University of Southern California |
| NCT02615002 | Phase 2 | Nov 1, 2015 | Neurim Pharmaceuticals Ltd., University of Southern California |
| NCT01489969 | Phase 2 | Dec 1, 2011 | Neurim Pharmaceuticals Ltd. |
| NCT01114126 | Phase 1 | Apr 1, 2010 | Forenap Pharma, Neurim Pharmaceuticals Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurim Pharmaceuticals Ltd. | For profit | 4 | 4 | 3 | 2010 |
| University of Southern California | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Forenap Pharma | For profit | 1 | 0 | 1 | 2010 |
| Syneos Health | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1